These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 26787277)

  • 1. CNS cancer: Breaking boundaries - IDH mutations in glioma.
    Killock D
    Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26787277
    [No Abstract]   [Full Text] [Related]  

  • 2. Bringing IDH into the Fold.
    Zadeh G; Aldape K
    Cancer Cell; 2016 Feb; 29(2):139-40. PubMed ID: 26859452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.
    Ing-Simmons E; Merkenschlager M
    Trends Mol Med; 2016 Mar; 22(3):185-187. PubMed ID: 26856236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer: Oncogene brought into the loop.
    Grimmer MR; Costello JF
    Nature; 2016 Jan; 529(7584):34-5. PubMed ID: 26700812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
    Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
    Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutation status in prostate cancer.
    Ghiam AF; Cairns RA; Thoms J; Dal Pra A; Ahmed O; Meng A; Mak TW; Bristow RG
    Oncogene; 2012 Aug; 31(33):3826. PubMed ID: 22120718
    [No Abstract]   [Full Text] [Related]  

  • 11. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
    Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
    Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
    Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
    Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.
    Ferroli P; Acerbi F; Finocchiaro G
    World Neurosurg; 2010 Apr; 73(4):234-6. PubMed ID: 20849763
    [No Abstract]   [Full Text] [Related]  

  • 17. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 19. IDH1 mutation detection by droplet digital PCR in glioma.
    Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
    Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutation in glioma: new insights and promises for the future.
    Turkalp Z; Karamchandani J; Das S
    JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.